Looking for the outcomes we love in all the wrong places: the questionable value of biomarkers and investments in chronic care disease management interventions.
Curtiss
Frederic R
FR
Fairman
Kathleen A
KA
D015415:Biomarkers; D002784:Cholesterol / Q000097:blood; D002908:Chronic Disease / Q000191:economics / Q000453:epidemiology / Q000628:therapy*; D003365:Costs and Cost Analysis; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000628:therapy; D019468:Disease Management; D019317:Evidence-Based Medicine; D006442:Glycated Hemoglobin / Q000032:analysis; D006293:Health Promotion; D006801:Humans; D008484:Medicaid; D006278:Medicare; D012308:Risk Management; D014481:United States
D015415:Biomarkers; D002784:Cholesterol; D006442:Glycated Hemoglobin